Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Spark Therapeutics Inc    ONCE

SPARK THERAPEUTICS INC

(ONCE)
  Report  
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Spark Therapeutics : Roche says $4.3 billion Spark offer still on track for June completion

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/03/2019 | 04:20am EDT
The logo of Swiss pharmaceutical company Roche is seen outside the Shanghai Roche Pharmaceutical Co. Ltd. headquarters in Shanghai

ZURICH (Reuters) - Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.

The Swiss company said it was extending its offer to May 2 from the original deadline of Wednesday, having received support from holders of only 29.4 percent of Spark shares. It needs a majority for its offer to go through.

A spokesman said Roche remained confident the deal would be completed by the end of June.

"All terms and conditions of the offer shall remain unchanged during the extended period," Roche said in a statement on the $114.50 per share offer it announced in February.

Roche also said a review of the acquisition by the U.S. Federal Trade Commission (FTC), the government agency which seeks to prevent anti-competitive practices, was taking more time than anticipated and its plans had had to be refiled.

It did not give any further detail on the refiling but said it had been agreed with the FTC and with Spark.

"The FTC review and clearance is required for the deal to be completed and needs more time," a Roche spokesman said.

"The deal is not in doubt at all and we expect it will be completed according to our guidance in the first half of 2019. There needs to be more than 50 percent of the shares to be tendered, but we believe our offer to be full and fair and it has been recommended by the board of Spark," the spokesman added.

GENETIC MATERIAL

Spark shares closed at $114.01 on Tuesday. Roche shares were down 0.3 percent in early trade.

Gene therapies use specially engineered viruses to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition.

Roche offered more than twice the Philadelphia-based company's closing price on Feb. 22 for a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for hemophilia and neurodegenerative disorders such as Huntington's disease.

The offer came as rivals including Novartis also move into gene therapy, where treatments for rare, inherited diseases command some of the highest prices in medicine.

Spark's blindness therapy Luxturna for instance is priced at $850,000 per patient. The treatment had sales of $27 million in 2018.

However Spark faces at least three lawsuits in the United States by shareholders challenging the sale, on grounds that it undervalues Spark's stock and is unfair to shareholders.

Roche on Wednesday declined to comment on the lawsuits.

Roche Chief Executive Severin Schwan is interested in gene therapies to help compensate for patent losses on his $21 billion per year trio of cancer medicines Rituxan, Herceptin and Avastin, which are facing competition from cheaper copies.

Spark, which also has product candidates that have shown promising early results in patients with hemophilia, reduced its net loss to $78.7 million in 2018, while revenue increased to $64.7 million.

(Editing by David Holmes)

By John Revill and John Miller

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING LTD. 0.63% 271.2 Delayed Quote.11.42%
SPARK THERAPEUTICS INC End-of-day quote.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SPARK THERAPEUTICS INC
05/18ROCHE : suffers third delay on Spark deal
AQ
05/16ROCHE : extends offer period in $4.3bn Spark takeover
AQ
05/15SPARK THERAPEUTICS : Roche and Spark Therapeutics, Inc. announce expected refili..
AQ
05/14Roche Extends Offer Period for Spark Therapeutics
DJ
05/14SPARK THERAPEUTICS : Roche pushes back Spark takeover again as regulatory review..
RE
05/14ROCHE : and Spark Therapeutics, Inc. announce expected refiling date of Premerge..
AQ
05/10SPARK THERAPEUTICS : Management's Discussion and Analysis of Financial Condition..
AQ
04/29SPARK THERAPEUTICS : Roche and Spark Therapeutics, Inc. announce withdrawal and ..
AQ
04/26SPARK THERAPEUTICS : Roche faces further delay in $4.3 billion Spark deal amid F..
RE
04/17Spark Therapeutics Announces Sponsorship of Believe Limited's First-Ever Scie..
GL
More news
Financials ($)
Sales 2019 111 M
EBIT 2019 -202 M
Net income 2019 -190 M
Finance 2019 326 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 35,2x
EV / Sales 2020 22,6x
Capitalization 4 238 M
Chart SPARK THERAPEUTICS INC
Duration : Period :
Spark Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 107 $
Spread / Average Target -2,7%
EPS Revisions
Managers
NameTitle
Jeffrey D. Marrazzo Chief Executive Officer & Director
Katherine A. High President, Director & Head-Research & Development
Steven M. Altschuler Chairman
Stephen W. Webster CFO & Principal Accounting Officer
Federico Mingozzi Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
SPARK THERAPEUTICS INC4 238
GILEAD SCIENCES6.94%85 054
VERTEX PHARMACEUTICALS3.66%43 994
REGENERON PHARMACEUTICALS-16.32%33 671
GENMAB14.61%11 324
SAREPTA THERAPEUTICS INC10.73%8 961